trial

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCTId NCT00130676
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 257 (actual)
Sponsored by Corcept Therapeutics
Primary completion 2006-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
257 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-09
Primary completion
2006-06
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Mifepristone

Sponsors

Corcept TherapeuticsLead Sponsor

Investigators

1
Katherine Beebe, PhDStudy Director

Sites

23 total
Pico Rivera, United StatesRiverside, United StatesSan Diego, United StatesJacksonville, United StatesPompano Beach, United StatesAtlanta, United StatesOak Brook, United StatesGreenwood, United StatesFarmington Hills, United StatesLas Vegas, United StatesClementon, United StatesNewark, United States

Linked catalysts

1
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depres — primary completion2006-06

Facts & assertions

4 sourced
Enrollment
257
Phase
PHASE3
Primary Completion Date
2006-06
Status
COMPLETED
relationships
The graph out of here
drug
Mifepristone
drug
lead_sponsor
Corcept Therapeutics
company
indication
Major Depressive Disorder
indication
Psychotic Disorders
indication
Depressive Disorder, Major
indication
investigator
Katherine Beebe, PhD
person